Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific’s Improving ICD Sales Offset Slow Stent Revenues In Q1

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific's recent resolution of a warning letter pertaining to quality control deficiencies at one of its cardiac rhythm management device manufacturing plants should help increase sales of the implants in the coming quarters, the firm says
Advertisement

Related Content

FDA Hands Boston Scientific Warning Letter For Clinical Trial Violations
FDA Hands Boston Scientific Warning Letter For Clinical Trial Violations
One Boston Scientific warning letter down
COURAGE Suggests Stents Do Not Benefit Stable Coronary Disease Patients
Medtronic Loses ICD Market Share, Looks Ahead To U.S. Market Rebound
Boston Scientific Expects To Be Ready For FDA Inspections By Summer
Advertisement
UsernamePublicRestriction

Register

MT024735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel